Research programme: dendritic cell vaccines - Argos/Kyowa Hakko Kirin

Drug Profile

Research programme: dendritic cell vaccines - Argos/Kyowa Hakko Kirin

Alternative Names: eCD/IL-4

Latest Information Update: 18 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argos Therapeutics Inc; Kirin Brewery
  • Developer Argos Therapeutics Inc
  • Class Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Infections
  • No development reported Diabetes mellitus

Most Recent Events

  • 18 Sep 2014 Early research is ongoing for Cancer and Infections in USA
  • 03 Aug 2010 Preclinical trials in Diabetes mellitus in USA (Parenteral)
  • 31 Dec 2009 Discontinued - Preclinical for Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top